Researcher Profile

Researcher Profile

Kevin L. Rakszawski, MD

Kevin L. Rakszawski, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
klr307@psu.edu

Research Interests

Dr. Kevin Rakszawski's research interests include end-of-life care in patients with hematologic malignancies; lymphoma therapeutics; and prevention and treatment of complications of blood and marrow transplantation.

  • Therapeutics
  • Acute Myeloid Leukemia
  • Stem Cells
  • Transplants
  • Survival
  • Systematic Reviews
  • T-Lymphocytes
  • Allogeneic Cells
  • Cohort Studies
  • Drug Therapy
  • Hematologic Neoplasms
  • Cell- and Tissue-Based Therapy

Clinical Trials

bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine Pre-conditioning followed by Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC Study)
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications

2021

Herrera, AF, Ahn, KW, Litovich, C, Chen, Y, Assal, A, Bashir, Q, Bayer, RL, Coleman, M, DeFilipp, Z, Farhadfar, N, Greenwood, M, Hahn, T, Horwitz, M, Jacobson, C, Jaglowski, S, Lachance, S, Langston, A, Mattar, B, Maziarz, RT, McGuirk, J, Mian, MAH, Nathan, S, Phillips, A, Rakszawski, K, Sengeloev, H, Shenoy, S, Stuart, R, Sauter, CS, Kharfan-Dabaja, MA & Hamadani, M 2021, 'Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome', Blood Advances, vol. 5, no. 18, pp. 3528-3539. https://doi.org/10.1182/bloodadvances.2021004865
Shah, N, Rakszawski, K, Nickolich, M, Ehmann, C, Wirk, B, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Mackey, G, Greiner, R, Brown, V, Claxton, D, Mineishi, S & Minagawa, K 2021, 'Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion', Annals of Hematology, vol. 100, no. 10, pp. 2585-2592. https://doi.org/10.1007/s00277-021-04616-7
Nine-I investigators 2021, 'Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study', The Lancet Haematology, vol. 8, no. 5, pp. e355-e364. https://doi.org/10.1016/S2352-3026(21)00060-0

2020

Van de Louw, A, Twomey, K, Habecker, N & Rakszawski, K 2021, 'Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study', Annals of Hematology, vol. 100, no. 1, pp. 229-237. https://doi.org/10.1007/s00277-020-04197-x

2019

Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107

2018

Rakszawski, K, Miki, K, Claxton, D, Wagner Jr., H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350. https://doi.org/10.1007/s12185-018-2431-5

2017

Leberfinger, AN, Behar, BJ, Williams, NC, Rakszawski, KL, Potochny, JD, MacKay, DR & Ravnic, DJ 2017, 'Breast implant-associated anaplastic large cell lymphoma: A systematic review', JAMA Surgery, vol. 152, no. 12, pp. 1161-1168. https://doi.org/10.1001/jamasurg.2017.4026

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)